General Information of DTT (ID: TTJSZTB)

DTT Name Nicotinic acetylcholine receptor (nAChR) DTT Info
Gene Name nAChR

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
5 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Atracurium DM42HXN Anaesthesia 9A78.6 Approved [1]
Cotinine DMCEZ1B Insecticide N.A. Approved [2]
Mecamylamine DMGQFYB Essential hypertension BA00 Approved [3]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [4]
Pancuronium DMB0VY8 Anaesthesia 9A78.6 Approved [1]
------------------------------------------------------------------------------------
12 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [5]
A-85380 DMHOLB7 N. A. N. A. Phase 2 [6]
ASM-024 DM35S2I Asthma CA23 Phase 2 [7]
BMS-954561 DM7XV4R Diabetic neuropathy 8C0Z Phase 2 [8]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [9]
NIC-002 DMKLJMI Nicotine dependence 6C4A.2 Phase 2 [10]
TRIDMAC DMWU41P Mood disorder 6A60-6E23 Phase 2 [11]
ATG002 DMB5X7Z Diabetic foot ulcer BD54 Phase 1/2 [12]
GANTACURIUM CHLORIDE DMN7QBE Anaesthesia 9A78.6 Phase 1/2 [13]
ND-0801 DMCDQX0 Attention deficit hyperactivity disorder 6A05.Z Phase 1/2 [14]
RPI-78M DMXKFOQ Multiple sclerosis 8A40 Phase 1 [15]
RPI-MN DM5OXPZ Amyotrophic lateral sclerosis 8B60.0 Phase 1 [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Clinical Trial Drug(s)
12 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Inaperisone DM05MCO Pollakiuria MF50.1 Discontinued in Preregistration [17]
ABT-418 DMNP72I Alzheimer disease 8A20 Discontinued in Phase 2 [18]
ABT-594 DMGMBCW N. A. N. A. Discontinued in Phase 2 [19]
ORG-9273 DMW1FT0 Paralysis 8B60 Discontinued in Phase 2 [20]
RJR-2403 DMOZEN6 Cognitive impairment 6D71 Discontinued in Phase 2 [6]
SIB-1553A DM7XC0U Alzheimer disease 8A20 Discontinued in Phase 2 [21]
ABT-202 DMG9Y80 Pain MG30-MG3Z Discontinued in Phase 1 [22]
ANQ-9040 DMRQFIE Paralysis 8B60 Discontinued in Phase 1 [23]
DBO-83 DM0JDCS N. A. N. A. Terminated [6]
NNC-90-0270 DM1SXG9 Alzheimer disease 8A20 Terminated [24]
SIB-1663 DMO4WB8 N. A. N. A. Terminated [6]
SIB-1765F DM6MSKT N. A. N. A. Terminated [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Discontinued Drug(s)
3 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
8-aminoquinolines DMN8QAF Discovery agent N.A. Investigative [26]
Epibatidine DMAGZD8 Discovery agent N.A. Investigative [21]
PROTOSTEMODIOL DMI6TKU Discovery agent N.A. Investigative [27]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
2 Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
3 Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
4 Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
7 Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
8 EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
9 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
10 Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
11 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
12 Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006.
13 Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 April; 112(4): 892-899.
14 Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex. Eur J Pharmacol. 1992 Mar 31;213(3):409-15.
18 Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82.
19 ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998 May;285(2):787-94.
20 Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent. Anesth Analg. 1991 Jun;72(6):811-6.
21 The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 1998;62(17-18):1601-6.
22 Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs. 2004 Jan;5(1):76-81.
23 Patent US20030087306 A1.
24 Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol. 2005 Jun;25(3-4):513-52.
25 Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.
26 Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40.
27 Alkaloids from stems and leaves of Stemona japonica and their insecticidal activities. J Nat Prod. 2008 Jan;71(1):112-6.